Global Granisetron Market

Granisetron Comprehensive Study by Application (Chemotherapy, Radiotherapy, Nausea, Gastroparesis, Postoperative), Forms (Injection, Tablet, Syrup, Tablet, Oral Drops), Drug type (Generic drug, Patent based drug), End User (Hospital, Drug Store) Players and Region - Global Market Outlook to 2030

Granisetron Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Granisetron
Granisetron is used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy. Granisetron is in a class of medications called 5-HT3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that causes nausea and vomiting

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that India and Germany Players will contribute the maximum growth to Global Granisetron market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Kyowa Kirin (Japan), Heron Therapeutics (United States), Fresenius Kabi (Germany), Hikma Pharmaceuticals (United Kingdom), Teva (Israel), Sandoz (Germany), Wockhardt (India), Aristo Pharmaceuticals Pvt Ltd (India), Mankind Pharma Ltd(India) and Cipla Ltd (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sun Pharmaceutical Industries Ltd(India), Biochem Pharmaceutical Industries(India), Vibcare Pharma Pvt Ltd(India) and Dr Reddy's (India).

Segmentation Overview
AMA Research has segmented the market of Global Granisetron market by , Application (Chemotherapy, Radiotherapy, Nausea, Gastroparesis and Postoperative) and Region.



On the basis of geography, the market of Granisetron has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Forms, the sub-segment i.e. Injection will boost the Granisetron market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug type, the sub-segment i.e. Generic drug will boost the Granisetron market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Granisetron market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing pharmaceutical research and funding

Market Growth Drivers:
The rise in the prevalence of cancers

Challenges:
Key competition between players

Restraints:
The adverse effect of the granisetron

Opportunities:
Increasing demand for personalized medicine

Market Leaders and their expansionary development strategies
In January 2022, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that it has entered into a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company focused on discovering and delivering novel medicines.
In November 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced financial results for the three and nine months ended September 30, 2021 and highlighted recent corporate updates.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Granisetron Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Chemotherapy
  • Radiotherapy
  • Nausea
  • Gastroparesis
  • Postoperative
By Forms
  • Injection
  • Tablet
  • Syrup
  • Tablet
  • Oral Drops

By Drug type
  • Generic drug
  • Patent based drug

By End User
  • Hospital
  • Drug Store

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rise in the prevalence of cancers
    • 3.3. Market Challenges
      • 3.3.1. Key competition between players
    • 3.4. Market Trends
      • 3.4.1. Increasing pharmaceutical research and funding
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Granisetron, by Application, Forms, Drug type, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Granisetron (Value)
      • 5.2.1. Global Granisetron by: Application (Value)
        • 5.2.1.1. Chemotherapy
        • 5.2.1.2. Radiotherapy
        • 5.2.1.3. Nausea
        • 5.2.1.4. Gastroparesis
        • 5.2.1.5. Postoperative
      • 5.2.2. Global Granisetron by: Forms (Value)
        • 5.2.2.1. Injection
        • 5.2.2.2. Tablet
        • 5.2.2.3. Syrup
        • 5.2.2.4. Tablet
        • 5.2.2.5. Oral Drops
      • 5.2.3. Global Granisetron by: Drug type (Value)
        • 5.2.3.1. Generic drug
        • 5.2.3.2. Patent based drug
      • 5.2.4. Global Granisetron by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Drug Store
      • 5.2.5. Global Granisetron Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Granisetron (Volume)
      • 5.3.1. Global Granisetron by: Application (Volume)
        • 5.3.1.1. Chemotherapy
        • 5.3.1.2. Radiotherapy
        • 5.3.1.3. Nausea
        • 5.3.1.4. Gastroparesis
        • 5.3.1.5. Postoperative
      • 5.3.2. Global Granisetron by: Forms (Volume)
        • 5.3.2.1. Injection
        • 5.3.2.2. Tablet
        • 5.3.2.3. Syrup
        • 5.3.2.4. Tablet
        • 5.3.2.5. Oral Drops
      • 5.3.3. Global Granisetron by: Drug type (Volume)
        • 5.3.3.1. Generic drug
        • 5.3.3.2. Patent based drug
      • 5.3.4. Global Granisetron by: End User (Volume)
        • 5.3.4.1. Hospital
        • 5.3.4.2. Drug Store
      • 5.3.5. Global Granisetron Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Granisetron (Price)
  • 6. Granisetron: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Kyowa Kirin (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Heron Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Fresenius Kabi (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Wockhardt (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aristo Pharmaceuticals Pvt Ltd (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mankind Pharma Ltd(India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cipla Ltd (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Granisetron Sale, by Application, Forms, Drug type, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Granisetron (Value)
      • 7.2.1. Global Granisetron by: Application (Value)
        • 7.2.1.1. Chemotherapy
        • 7.2.1.2. Radiotherapy
        • 7.2.1.3. Nausea
        • 7.2.1.4. Gastroparesis
        • 7.2.1.5. Postoperative
      • 7.2.2. Global Granisetron by: Forms (Value)
        • 7.2.2.1. Injection
        • 7.2.2.2. Tablet
        • 7.2.2.3. Syrup
        • 7.2.2.4. Tablet
        • 7.2.2.5. Oral Drops
      • 7.2.3. Global Granisetron by: Drug type (Value)
        • 7.2.3.1. Generic drug
        • 7.2.3.2. Patent based drug
      • 7.2.4. Global Granisetron by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Drug Store
      • 7.2.5. Global Granisetron Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Granisetron (Volume)
      • 7.3.1. Global Granisetron by: Application (Volume)
        • 7.3.1.1. Chemotherapy
        • 7.3.1.2. Radiotherapy
        • 7.3.1.3. Nausea
        • 7.3.1.4. Gastroparesis
        • 7.3.1.5. Postoperative
      • 7.3.2. Global Granisetron by: Forms (Volume)
        • 7.3.2.1. Injection
        • 7.3.2.2. Tablet
        • 7.3.2.3. Syrup
        • 7.3.2.4. Tablet
        • 7.3.2.5. Oral Drops
      • 7.3.3. Global Granisetron by: Drug type (Volume)
        • 7.3.3.1. Generic drug
        • 7.3.3.2. Patent based drug
      • 7.3.4. Global Granisetron by: End User (Volume)
        • 7.3.4.1. Hospital
        • 7.3.4.2. Drug Store
      • 7.3.5. Global Granisetron Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Granisetron (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Granisetron: by Application(USD Million)
  • Table 2. Granisetron Chemotherapy , by Region USD Million (2018-2023)
  • Table 3. Granisetron Radiotherapy , by Region USD Million (2018-2023)
  • Table 4. Granisetron Nausea , by Region USD Million (2018-2023)
  • Table 5. Granisetron Gastroparesis , by Region USD Million (2018-2023)
  • Table 6. Granisetron Postoperative , by Region USD Million (2018-2023)
  • Table 7. Granisetron: by Forms(USD Million)
  • Table 8. Granisetron Injection , by Region USD Million (2018-2023)
  • Table 9. Granisetron Tablet , by Region USD Million (2018-2023)
  • Table 10. Granisetron Syrup , by Region USD Million (2018-2023)
  • Table 11. Granisetron Tablet , by Region USD Million (2018-2023)
  • Table 12. Granisetron Oral Drops , by Region USD Million (2018-2023)
  • Table 13. Granisetron: by Drug type(USD Million)
  • Table 14. Granisetron Generic drug , by Region USD Million (2018-2023)
  • Table 15. Granisetron Patent based drug , by Region USD Million (2018-2023)
  • Table 16. Granisetron: by End User(USD Million)
  • Table 17. Granisetron Hospital , by Region USD Million (2018-2023)
  • Table 18. Granisetron Drug Store , by Region USD Million (2018-2023)
  • Table 19. South America Granisetron, by Country USD Million (2018-2023)
  • Table 20. South America Granisetron, by Application USD Million (2018-2023)
  • Table 21. South America Granisetron, by Forms USD Million (2018-2023)
  • Table 22. South America Granisetron, by Drug type USD Million (2018-2023)
  • Table 23. South America Granisetron, by End User USD Million (2018-2023)
  • Table 24. Brazil Granisetron, by Application USD Million (2018-2023)
  • Table 25. Brazil Granisetron, by Forms USD Million (2018-2023)
  • Table 26. Brazil Granisetron, by Drug type USD Million (2018-2023)
  • Table 27. Brazil Granisetron, by End User USD Million (2018-2023)
  • Table 28. Argentina Granisetron, by Application USD Million (2018-2023)
  • Table 29. Argentina Granisetron, by Forms USD Million (2018-2023)
  • Table 30. Argentina Granisetron, by Drug type USD Million (2018-2023)
  • Table 31. Argentina Granisetron, by End User USD Million (2018-2023)
  • Table 32. Rest of South America Granisetron, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Granisetron, by Forms USD Million (2018-2023)
  • Table 34. Rest of South America Granisetron, by Drug type USD Million (2018-2023)
  • Table 35. Rest of South America Granisetron, by End User USD Million (2018-2023)
  • Table 36. Asia Pacific Granisetron, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Granisetron, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Granisetron, by Forms USD Million (2018-2023)
  • Table 39. Asia Pacific Granisetron, by Drug type USD Million (2018-2023)
  • Table 40. Asia Pacific Granisetron, by End User USD Million (2018-2023)
  • Table 41. China Granisetron, by Application USD Million (2018-2023)
  • Table 42. China Granisetron, by Forms USD Million (2018-2023)
  • Table 43. China Granisetron, by Drug type USD Million (2018-2023)
  • Table 44. China Granisetron, by End User USD Million (2018-2023)
  • Table 45. Japan Granisetron, by Application USD Million (2018-2023)
  • Table 46. Japan Granisetron, by Forms USD Million (2018-2023)
  • Table 47. Japan Granisetron, by Drug type USD Million (2018-2023)
  • Table 48. Japan Granisetron, by End User USD Million (2018-2023)
  • Table 49. India Granisetron, by Application USD Million (2018-2023)
  • Table 50. India Granisetron, by Forms USD Million (2018-2023)
  • Table 51. India Granisetron, by Drug type USD Million (2018-2023)
  • Table 52. India Granisetron, by End User USD Million (2018-2023)
  • Table 53. South Korea Granisetron, by Application USD Million (2018-2023)
  • Table 54. South Korea Granisetron, by Forms USD Million (2018-2023)
  • Table 55. South Korea Granisetron, by Drug type USD Million (2018-2023)
  • Table 56. South Korea Granisetron, by End User USD Million (2018-2023)
  • Table 57. Taiwan Granisetron, by Application USD Million (2018-2023)
  • Table 58. Taiwan Granisetron, by Forms USD Million (2018-2023)
  • Table 59. Taiwan Granisetron, by Drug type USD Million (2018-2023)
  • Table 60. Taiwan Granisetron, by End User USD Million (2018-2023)
  • Table 61. Australia Granisetron, by Application USD Million (2018-2023)
  • Table 62. Australia Granisetron, by Forms USD Million (2018-2023)
  • Table 63. Australia Granisetron, by Drug type USD Million (2018-2023)
  • Table 64. Australia Granisetron, by End User USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Granisetron, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Granisetron, by Forms USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Granisetron, by Drug type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Granisetron, by End User USD Million (2018-2023)
  • Table 69. Europe Granisetron, by Country USD Million (2018-2023)
  • Table 70. Europe Granisetron, by Application USD Million (2018-2023)
  • Table 71. Europe Granisetron, by Forms USD Million (2018-2023)
  • Table 72. Europe Granisetron, by Drug type USD Million (2018-2023)
  • Table 73. Europe Granisetron, by End User USD Million (2018-2023)
  • Table 74. Germany Granisetron, by Application USD Million (2018-2023)
  • Table 75. Germany Granisetron, by Forms USD Million (2018-2023)
  • Table 76. Germany Granisetron, by Drug type USD Million (2018-2023)
  • Table 77. Germany Granisetron, by End User USD Million (2018-2023)
  • Table 78. France Granisetron, by Application USD Million (2018-2023)
  • Table 79. France Granisetron, by Forms USD Million (2018-2023)
  • Table 80. France Granisetron, by Drug type USD Million (2018-2023)
  • Table 81. France Granisetron, by End User USD Million (2018-2023)
  • Table 82. Italy Granisetron, by Application USD Million (2018-2023)
  • Table 83. Italy Granisetron, by Forms USD Million (2018-2023)
  • Table 84. Italy Granisetron, by Drug type USD Million (2018-2023)
  • Table 85. Italy Granisetron, by End User USD Million (2018-2023)
  • Table 86. United Kingdom Granisetron, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Granisetron, by Forms USD Million (2018-2023)
  • Table 88. United Kingdom Granisetron, by Drug type USD Million (2018-2023)
  • Table 89. United Kingdom Granisetron, by End User USD Million (2018-2023)
  • Table 90. Netherlands Granisetron, by Application USD Million (2018-2023)
  • Table 91. Netherlands Granisetron, by Forms USD Million (2018-2023)
  • Table 92. Netherlands Granisetron, by Drug type USD Million (2018-2023)
  • Table 93. Netherlands Granisetron, by End User USD Million (2018-2023)
  • Table 94. Rest of Europe Granisetron, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Granisetron, by Forms USD Million (2018-2023)
  • Table 96. Rest of Europe Granisetron, by Drug type USD Million (2018-2023)
  • Table 97. Rest of Europe Granisetron, by End User USD Million (2018-2023)
  • Table 98. MEA Granisetron, by Country USD Million (2018-2023)
  • Table 99. MEA Granisetron, by Application USD Million (2018-2023)
  • Table 100. MEA Granisetron, by Forms USD Million (2018-2023)
  • Table 101. MEA Granisetron, by Drug type USD Million (2018-2023)
  • Table 102. MEA Granisetron, by End User USD Million (2018-2023)
  • Table 103. Middle East Granisetron, by Application USD Million (2018-2023)
  • Table 104. Middle East Granisetron, by Forms USD Million (2018-2023)
  • Table 105. Middle East Granisetron, by Drug type USD Million (2018-2023)
  • Table 106. Middle East Granisetron, by End User USD Million (2018-2023)
  • Table 107. Africa Granisetron, by Application USD Million (2018-2023)
  • Table 108. Africa Granisetron, by Forms USD Million (2018-2023)
  • Table 109. Africa Granisetron, by Drug type USD Million (2018-2023)
  • Table 110. Africa Granisetron, by End User USD Million (2018-2023)
  • Table 111. North America Granisetron, by Country USD Million (2018-2023)
  • Table 112. North America Granisetron, by Application USD Million (2018-2023)
  • Table 113. North America Granisetron, by Forms USD Million (2018-2023)
  • Table 114. North America Granisetron, by Drug type USD Million (2018-2023)
  • Table 115. North America Granisetron, by End User USD Million (2018-2023)
  • Table 116. United States Granisetron, by Application USD Million (2018-2023)
  • Table 117. United States Granisetron, by Forms USD Million (2018-2023)
  • Table 118. United States Granisetron, by Drug type USD Million (2018-2023)
  • Table 119. United States Granisetron, by End User USD Million (2018-2023)
  • Table 120. Canada Granisetron, by Application USD Million (2018-2023)
  • Table 121. Canada Granisetron, by Forms USD Million (2018-2023)
  • Table 122. Canada Granisetron, by Drug type USD Million (2018-2023)
  • Table 123. Canada Granisetron, by End User USD Million (2018-2023)
  • Table 124. Mexico Granisetron, by Application USD Million (2018-2023)
  • Table 125. Mexico Granisetron, by Forms USD Million (2018-2023)
  • Table 126. Mexico Granisetron, by Drug type USD Million (2018-2023)
  • Table 127. Mexico Granisetron, by End User USD Million (2018-2023)
  • Table 128. Granisetron Sales: by Application(K Tons)
  • Table 129. Granisetron Sales Chemotherapy , by Region K Tons (2018-2023)
  • Table 130. Granisetron Sales Radiotherapy , by Region K Tons (2018-2023)
  • Table 131. Granisetron Sales Nausea , by Region K Tons (2018-2023)
  • Table 132. Granisetron Sales Gastroparesis , by Region K Tons (2018-2023)
  • Table 133. Granisetron Sales Postoperative , by Region K Tons (2018-2023)
  • Table 134. Granisetron Sales: by Forms(K Tons)
  • Table 135. Granisetron Sales Injection , by Region K Tons (2018-2023)
  • Table 136. Granisetron Sales Tablet , by Region K Tons (2018-2023)
  • Table 137. Granisetron Sales Syrup , by Region K Tons (2018-2023)
  • Table 138. Granisetron Sales Tablet , by Region K Tons (2018-2023)
  • Table 139. Granisetron Sales Oral Drops , by Region K Tons (2018-2023)
  • Table 140. Granisetron Sales: by Drug type(K Tons)
  • Table 141. Granisetron Sales Generic drug , by Region K Tons (2018-2023)
  • Table 142. Granisetron Sales Patent based drug , by Region K Tons (2018-2023)
  • Table 143. Granisetron Sales: by End User(K Tons)
  • Table 144. Granisetron Sales Hospital , by Region K Tons (2018-2023)
  • Table 145. Granisetron Sales Drug Store , by Region K Tons (2018-2023)
  • Table 146. South America Granisetron Sales, by Country K Tons (2018-2023)
  • Table 147. South America Granisetron Sales, by Application K Tons (2018-2023)
  • Table 148. South America Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 149. South America Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 150. South America Granisetron Sales, by End User K Tons (2018-2023)
  • Table 151. Brazil Granisetron Sales, by Application K Tons (2018-2023)
  • Table 152. Brazil Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 153. Brazil Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 154. Brazil Granisetron Sales, by End User K Tons (2018-2023)
  • Table 155. Argentina Granisetron Sales, by Application K Tons (2018-2023)
  • Table 156. Argentina Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 157. Argentina Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 158. Argentina Granisetron Sales, by End User K Tons (2018-2023)
  • Table 159. Rest of South America Granisetron Sales, by Application K Tons (2018-2023)
  • Table 160. Rest of South America Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 161. Rest of South America Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 162. Rest of South America Granisetron Sales, by End User K Tons (2018-2023)
  • Table 163. Asia Pacific Granisetron Sales, by Country K Tons (2018-2023)
  • Table 164. Asia Pacific Granisetron Sales, by Application K Tons (2018-2023)
  • Table 165. Asia Pacific Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 166. Asia Pacific Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 167. Asia Pacific Granisetron Sales, by End User K Tons (2018-2023)
  • Table 168. China Granisetron Sales, by Application K Tons (2018-2023)
  • Table 169. China Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 170. China Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 171. China Granisetron Sales, by End User K Tons (2018-2023)
  • Table 172. Japan Granisetron Sales, by Application K Tons (2018-2023)
  • Table 173. Japan Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 174. Japan Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 175. Japan Granisetron Sales, by End User K Tons (2018-2023)
  • Table 176. India Granisetron Sales, by Application K Tons (2018-2023)
  • Table 177. India Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 178. India Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 179. India Granisetron Sales, by End User K Tons (2018-2023)
  • Table 180. South Korea Granisetron Sales, by Application K Tons (2018-2023)
  • Table 181. South Korea Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 182. South Korea Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 183. South Korea Granisetron Sales, by End User K Tons (2018-2023)
  • Table 184. Taiwan Granisetron Sales, by Application K Tons (2018-2023)
  • Table 185. Taiwan Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 186. Taiwan Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 187. Taiwan Granisetron Sales, by End User K Tons (2018-2023)
  • Table 188. Australia Granisetron Sales, by Application K Tons (2018-2023)
  • Table 189. Australia Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 190. Australia Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 191. Australia Granisetron Sales, by End User K Tons (2018-2023)
  • Table 192. Rest of Asia-Pacific Granisetron Sales, by Application K Tons (2018-2023)
  • Table 193. Rest of Asia-Pacific Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 194. Rest of Asia-Pacific Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 195. Rest of Asia-Pacific Granisetron Sales, by End User K Tons (2018-2023)
  • Table 196. Europe Granisetron Sales, by Country K Tons (2018-2023)
  • Table 197. Europe Granisetron Sales, by Application K Tons (2018-2023)
  • Table 198. Europe Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 199. Europe Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 200. Europe Granisetron Sales, by End User K Tons (2018-2023)
  • Table 201. Germany Granisetron Sales, by Application K Tons (2018-2023)
  • Table 202. Germany Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 203. Germany Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 204. Germany Granisetron Sales, by End User K Tons (2018-2023)
  • Table 205. France Granisetron Sales, by Application K Tons (2018-2023)
  • Table 206. France Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 207. France Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 208. France Granisetron Sales, by End User K Tons (2018-2023)
  • Table 209. Italy Granisetron Sales, by Application K Tons (2018-2023)
  • Table 210. Italy Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 211. Italy Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 212. Italy Granisetron Sales, by End User K Tons (2018-2023)
  • Table 213. United Kingdom Granisetron Sales, by Application K Tons (2018-2023)
  • Table 214. United Kingdom Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 215. United Kingdom Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 216. United Kingdom Granisetron Sales, by End User K Tons (2018-2023)
  • Table 217. Netherlands Granisetron Sales, by Application K Tons (2018-2023)
  • Table 218. Netherlands Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 219. Netherlands Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 220. Netherlands Granisetron Sales, by End User K Tons (2018-2023)
  • Table 221. Rest of Europe Granisetron Sales, by Application K Tons (2018-2023)
  • Table 222. Rest of Europe Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 223. Rest of Europe Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 224. Rest of Europe Granisetron Sales, by End User K Tons (2018-2023)
  • Table 225. MEA Granisetron Sales, by Country K Tons (2018-2023)
  • Table 226. MEA Granisetron Sales, by Application K Tons (2018-2023)
  • Table 227. MEA Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 228. MEA Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 229. MEA Granisetron Sales, by End User K Tons (2018-2023)
  • Table 230. Middle East Granisetron Sales, by Application K Tons (2018-2023)
  • Table 231. Middle East Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 232. Middle East Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 233. Middle East Granisetron Sales, by End User K Tons (2018-2023)
  • Table 234. Africa Granisetron Sales, by Application K Tons (2018-2023)
  • Table 235. Africa Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 236. Africa Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 237. Africa Granisetron Sales, by End User K Tons (2018-2023)
  • Table 238. North America Granisetron Sales, by Country K Tons (2018-2023)
  • Table 239. North America Granisetron Sales, by Application K Tons (2018-2023)
  • Table 240. North America Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 241. North America Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 242. North America Granisetron Sales, by End User K Tons (2018-2023)
  • Table 243. United States Granisetron Sales, by Application K Tons (2018-2023)
  • Table 244. United States Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 245. United States Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 246. United States Granisetron Sales, by End User K Tons (2018-2023)
  • Table 247. Canada Granisetron Sales, by Application K Tons (2018-2023)
  • Table 248. Canada Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 249. Canada Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 250. Canada Granisetron Sales, by End User K Tons (2018-2023)
  • Table 251. Mexico Granisetron Sales, by Application K Tons (2018-2023)
  • Table 252. Mexico Granisetron Sales, by Forms K Tons (2018-2023)
  • Table 253. Mexico Granisetron Sales, by Drug type K Tons (2018-2023)
  • Table 254. Mexico Granisetron Sales, by End User K Tons (2018-2023)
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Granisetron: by Application(USD Million)
  • Table 266. Granisetron Chemotherapy , by Region USD Million (2025-2030)
  • Table 267. Granisetron Radiotherapy , by Region USD Million (2025-2030)
  • Table 268. Granisetron Nausea , by Region USD Million (2025-2030)
  • Table 269. Granisetron Gastroparesis , by Region USD Million (2025-2030)
  • Table 270. Granisetron Postoperative , by Region USD Million (2025-2030)
  • Table 271. Granisetron: by Forms(USD Million)
  • Table 272. Granisetron Injection , by Region USD Million (2025-2030)
  • Table 273. Granisetron Tablet , by Region USD Million (2025-2030)
  • Table 274. Granisetron Syrup , by Region USD Million (2025-2030)
  • Table 275. Granisetron Tablet , by Region USD Million (2025-2030)
  • Table 276. Granisetron Oral Drops , by Region USD Million (2025-2030)
  • Table 277. Granisetron: by Drug type(USD Million)
  • Table 278. Granisetron Generic drug , by Region USD Million (2025-2030)
  • Table 279. Granisetron Patent based drug , by Region USD Million (2025-2030)
  • Table 280. Granisetron: by End User(USD Million)
  • Table 281. Granisetron Hospital , by Region USD Million (2025-2030)
  • Table 282. Granisetron Drug Store , by Region USD Million (2025-2030)
  • Table 283. South America Granisetron, by Country USD Million (2025-2030)
  • Table 284. South America Granisetron, by Application USD Million (2025-2030)
  • Table 285. South America Granisetron, by Forms USD Million (2025-2030)
  • Table 286. South America Granisetron, by Drug type USD Million (2025-2030)
  • Table 287. South America Granisetron, by End User USD Million (2025-2030)
  • Table 288. Brazil Granisetron, by Application USD Million (2025-2030)
  • Table 289. Brazil Granisetron, by Forms USD Million (2025-2030)
  • Table 290. Brazil Granisetron, by Drug type USD Million (2025-2030)
  • Table 291. Brazil Granisetron, by End User USD Million (2025-2030)
  • Table 292. Argentina Granisetron, by Application USD Million (2025-2030)
  • Table 293. Argentina Granisetron, by Forms USD Million (2025-2030)
  • Table 294. Argentina Granisetron, by Drug type USD Million (2025-2030)
  • Table 295. Argentina Granisetron, by End User USD Million (2025-2030)
  • Table 296. Rest of South America Granisetron, by Application USD Million (2025-2030)
  • Table 297. Rest of South America Granisetron, by Forms USD Million (2025-2030)
  • Table 298. Rest of South America Granisetron, by Drug type USD Million (2025-2030)
  • Table 299. Rest of South America Granisetron, by End User USD Million (2025-2030)
  • Table 300. Asia Pacific Granisetron, by Country USD Million (2025-2030)
  • Table 301. Asia Pacific Granisetron, by Application USD Million (2025-2030)
  • Table 302. Asia Pacific Granisetron, by Forms USD Million (2025-2030)
  • Table 303. Asia Pacific Granisetron, by Drug type USD Million (2025-2030)
  • Table 304. Asia Pacific Granisetron, by End User USD Million (2025-2030)
  • Table 305. China Granisetron, by Application USD Million (2025-2030)
  • Table 306. China Granisetron, by Forms USD Million (2025-2030)
  • Table 307. China Granisetron, by Drug type USD Million (2025-2030)
  • Table 308. China Granisetron, by End User USD Million (2025-2030)
  • Table 309. Japan Granisetron, by Application USD Million (2025-2030)
  • Table 310. Japan Granisetron, by Forms USD Million (2025-2030)
  • Table 311. Japan Granisetron, by Drug type USD Million (2025-2030)
  • Table 312. Japan Granisetron, by End User USD Million (2025-2030)
  • Table 313. India Granisetron, by Application USD Million (2025-2030)
  • Table 314. India Granisetron, by Forms USD Million (2025-2030)
  • Table 315. India Granisetron, by Drug type USD Million (2025-2030)
  • Table 316. India Granisetron, by End User USD Million (2025-2030)
  • Table 317. South Korea Granisetron, by Application USD Million (2025-2030)
  • Table 318. South Korea Granisetron, by Forms USD Million (2025-2030)
  • Table 319. South Korea Granisetron, by Drug type USD Million (2025-2030)
  • Table 320. South Korea Granisetron, by End User USD Million (2025-2030)
  • Table 321. Taiwan Granisetron, by Application USD Million (2025-2030)
  • Table 322. Taiwan Granisetron, by Forms USD Million (2025-2030)
  • Table 323. Taiwan Granisetron, by Drug type USD Million (2025-2030)
  • Table 324. Taiwan Granisetron, by End User USD Million (2025-2030)
  • Table 325. Australia Granisetron, by Application USD Million (2025-2030)
  • Table 326. Australia Granisetron, by Forms USD Million (2025-2030)
  • Table 327. Australia Granisetron, by Drug type USD Million (2025-2030)
  • Table 328. Australia Granisetron, by End User USD Million (2025-2030)
  • Table 329. Rest of Asia-Pacific Granisetron, by Application USD Million (2025-2030)
  • Table 330. Rest of Asia-Pacific Granisetron, by Forms USD Million (2025-2030)
  • Table 331. Rest of Asia-Pacific Granisetron, by Drug type USD Million (2025-2030)
  • Table 332. Rest of Asia-Pacific Granisetron, by End User USD Million (2025-2030)
  • Table 333. Europe Granisetron, by Country USD Million (2025-2030)
  • Table 334. Europe Granisetron, by Application USD Million (2025-2030)
  • Table 335. Europe Granisetron, by Forms USD Million (2025-2030)
  • Table 336. Europe Granisetron, by Drug type USD Million (2025-2030)
  • Table 337. Europe Granisetron, by End User USD Million (2025-2030)
  • Table 338. Germany Granisetron, by Application USD Million (2025-2030)
  • Table 339. Germany Granisetron, by Forms USD Million (2025-2030)
  • Table 340. Germany Granisetron, by Drug type USD Million (2025-2030)
  • Table 341. Germany Granisetron, by End User USD Million (2025-2030)
  • Table 342. France Granisetron, by Application USD Million (2025-2030)
  • Table 343. France Granisetron, by Forms USD Million (2025-2030)
  • Table 344. France Granisetron, by Drug type USD Million (2025-2030)
  • Table 345. France Granisetron, by End User USD Million (2025-2030)
  • Table 346. Italy Granisetron, by Application USD Million (2025-2030)
  • Table 347. Italy Granisetron, by Forms USD Million (2025-2030)
  • Table 348. Italy Granisetron, by Drug type USD Million (2025-2030)
  • Table 349. Italy Granisetron, by End User USD Million (2025-2030)
  • Table 350. United Kingdom Granisetron, by Application USD Million (2025-2030)
  • Table 351. United Kingdom Granisetron, by Forms USD Million (2025-2030)
  • Table 352. United Kingdom Granisetron, by Drug type USD Million (2025-2030)
  • Table 353. United Kingdom Granisetron, by End User USD Million (2025-2030)
  • Table 354. Netherlands Granisetron, by Application USD Million (2025-2030)
  • Table 355. Netherlands Granisetron, by Forms USD Million (2025-2030)
  • Table 356. Netherlands Granisetron, by Drug type USD Million (2025-2030)
  • Table 357. Netherlands Granisetron, by End User USD Million (2025-2030)
  • Table 358. Rest of Europe Granisetron, by Application USD Million (2025-2030)
  • Table 359. Rest of Europe Granisetron, by Forms USD Million (2025-2030)
  • Table 360. Rest of Europe Granisetron, by Drug type USD Million (2025-2030)
  • Table 361. Rest of Europe Granisetron, by End User USD Million (2025-2030)
  • Table 362. MEA Granisetron, by Country USD Million (2025-2030)
  • Table 363. MEA Granisetron, by Application USD Million (2025-2030)
  • Table 364. MEA Granisetron, by Forms USD Million (2025-2030)
  • Table 365. MEA Granisetron, by Drug type USD Million (2025-2030)
  • Table 366. MEA Granisetron, by End User USD Million (2025-2030)
  • Table 367. Middle East Granisetron, by Application USD Million (2025-2030)
  • Table 368. Middle East Granisetron, by Forms USD Million (2025-2030)
  • Table 369. Middle East Granisetron, by Drug type USD Million (2025-2030)
  • Table 370. Middle East Granisetron, by End User USD Million (2025-2030)
  • Table 371. Africa Granisetron, by Application USD Million (2025-2030)
  • Table 372. Africa Granisetron, by Forms USD Million (2025-2030)
  • Table 373. Africa Granisetron, by Drug type USD Million (2025-2030)
  • Table 374. Africa Granisetron, by End User USD Million (2025-2030)
  • Table 375. North America Granisetron, by Country USD Million (2025-2030)
  • Table 376. North America Granisetron, by Application USD Million (2025-2030)
  • Table 377. North America Granisetron, by Forms USD Million (2025-2030)
  • Table 378. North America Granisetron, by Drug type USD Million (2025-2030)
  • Table 379. North America Granisetron, by End User USD Million (2025-2030)
  • Table 380. United States Granisetron, by Application USD Million (2025-2030)
  • Table 381. United States Granisetron, by Forms USD Million (2025-2030)
  • Table 382. United States Granisetron, by Drug type USD Million (2025-2030)
  • Table 383. United States Granisetron, by End User USD Million (2025-2030)
  • Table 384. Canada Granisetron, by Application USD Million (2025-2030)
  • Table 385. Canada Granisetron, by Forms USD Million (2025-2030)
  • Table 386. Canada Granisetron, by Drug type USD Million (2025-2030)
  • Table 387. Canada Granisetron, by End User USD Million (2025-2030)
  • Table 388. Mexico Granisetron, by Application USD Million (2025-2030)
  • Table 389. Mexico Granisetron, by Forms USD Million (2025-2030)
  • Table 390. Mexico Granisetron, by Drug type USD Million (2025-2030)
  • Table 391. Mexico Granisetron, by End User USD Million (2025-2030)
  • Table 392. Granisetron Sales: by Application(K Tons)
  • Table 393. Granisetron Sales Chemotherapy , by Region K Tons (2025-2030)
  • Table 394. Granisetron Sales Radiotherapy , by Region K Tons (2025-2030)
  • Table 395. Granisetron Sales Nausea , by Region K Tons (2025-2030)
  • Table 396. Granisetron Sales Gastroparesis , by Region K Tons (2025-2030)
  • Table 397. Granisetron Sales Postoperative , by Region K Tons (2025-2030)
  • Table 398. Granisetron Sales: by Forms(K Tons)
  • Table 399. Granisetron Sales Injection , by Region K Tons (2025-2030)
  • Table 400. Granisetron Sales Tablet , by Region K Tons (2025-2030)
  • Table 401. Granisetron Sales Syrup , by Region K Tons (2025-2030)
  • Table 402. Granisetron Sales Tablet , by Region K Tons (2025-2030)
  • Table 403. Granisetron Sales Oral Drops , by Region K Tons (2025-2030)
  • Table 404. Granisetron Sales: by Drug type(K Tons)
  • Table 405. Granisetron Sales Generic drug , by Region K Tons (2025-2030)
  • Table 406. Granisetron Sales Patent based drug , by Region K Tons (2025-2030)
  • Table 407. Granisetron Sales: by End User(K Tons)
  • Table 408. Granisetron Sales Hospital , by Region K Tons (2025-2030)
  • Table 409. Granisetron Sales Drug Store , by Region K Tons (2025-2030)
  • Table 410. South America Granisetron Sales, by Country K Tons (2025-2030)
  • Table 411. South America Granisetron Sales, by Application K Tons (2025-2030)
  • Table 412. South America Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 413. South America Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 414. South America Granisetron Sales, by End User K Tons (2025-2030)
  • Table 415. Brazil Granisetron Sales, by Application K Tons (2025-2030)
  • Table 416. Brazil Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 417. Brazil Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 418. Brazil Granisetron Sales, by End User K Tons (2025-2030)
  • Table 419. Argentina Granisetron Sales, by Application K Tons (2025-2030)
  • Table 420. Argentina Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 421. Argentina Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 422. Argentina Granisetron Sales, by End User K Tons (2025-2030)
  • Table 423. Rest of South America Granisetron Sales, by Application K Tons (2025-2030)
  • Table 424. Rest of South America Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 425. Rest of South America Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 426. Rest of South America Granisetron Sales, by End User K Tons (2025-2030)
  • Table 427. Asia Pacific Granisetron Sales, by Country K Tons (2025-2030)
  • Table 428. Asia Pacific Granisetron Sales, by Application K Tons (2025-2030)
  • Table 429. Asia Pacific Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 430. Asia Pacific Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 431. Asia Pacific Granisetron Sales, by End User K Tons (2025-2030)
  • Table 432. China Granisetron Sales, by Application K Tons (2025-2030)
  • Table 433. China Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 434. China Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 435. China Granisetron Sales, by End User K Tons (2025-2030)
  • Table 436. Japan Granisetron Sales, by Application K Tons (2025-2030)
  • Table 437. Japan Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 438. Japan Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 439. Japan Granisetron Sales, by End User K Tons (2025-2030)
  • Table 440. India Granisetron Sales, by Application K Tons (2025-2030)
  • Table 441. India Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 442. India Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 443. India Granisetron Sales, by End User K Tons (2025-2030)
  • Table 444. South Korea Granisetron Sales, by Application K Tons (2025-2030)
  • Table 445. South Korea Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 446. South Korea Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 447. South Korea Granisetron Sales, by End User K Tons (2025-2030)
  • Table 448. Taiwan Granisetron Sales, by Application K Tons (2025-2030)
  • Table 449. Taiwan Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 450. Taiwan Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 451. Taiwan Granisetron Sales, by End User K Tons (2025-2030)
  • Table 452. Australia Granisetron Sales, by Application K Tons (2025-2030)
  • Table 453. Australia Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 454. Australia Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 455. Australia Granisetron Sales, by End User K Tons (2025-2030)
  • Table 456. Rest of Asia-Pacific Granisetron Sales, by Application K Tons (2025-2030)
  • Table 457. Rest of Asia-Pacific Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 458. Rest of Asia-Pacific Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 459. Rest of Asia-Pacific Granisetron Sales, by End User K Tons (2025-2030)
  • Table 460. Europe Granisetron Sales, by Country K Tons (2025-2030)
  • Table 461. Europe Granisetron Sales, by Application K Tons (2025-2030)
  • Table 462. Europe Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 463. Europe Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 464. Europe Granisetron Sales, by End User K Tons (2025-2030)
  • Table 465. Germany Granisetron Sales, by Application K Tons (2025-2030)
  • Table 466. Germany Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 467. Germany Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 468. Germany Granisetron Sales, by End User K Tons (2025-2030)
  • Table 469. France Granisetron Sales, by Application K Tons (2025-2030)
  • Table 470. France Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 471. France Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 472. France Granisetron Sales, by End User K Tons (2025-2030)
  • Table 473. Italy Granisetron Sales, by Application K Tons (2025-2030)
  • Table 474. Italy Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 475. Italy Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 476. Italy Granisetron Sales, by End User K Tons (2025-2030)
  • Table 477. United Kingdom Granisetron Sales, by Application K Tons (2025-2030)
  • Table 478. United Kingdom Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 479. United Kingdom Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 480. United Kingdom Granisetron Sales, by End User K Tons (2025-2030)
  • Table 481. Netherlands Granisetron Sales, by Application K Tons (2025-2030)
  • Table 482. Netherlands Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 483. Netherlands Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 484. Netherlands Granisetron Sales, by End User K Tons (2025-2030)
  • Table 485. Rest of Europe Granisetron Sales, by Application K Tons (2025-2030)
  • Table 486. Rest of Europe Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 487. Rest of Europe Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 488. Rest of Europe Granisetron Sales, by End User K Tons (2025-2030)
  • Table 489. MEA Granisetron Sales, by Country K Tons (2025-2030)
  • Table 490. MEA Granisetron Sales, by Application K Tons (2025-2030)
  • Table 491. MEA Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 492. MEA Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 493. MEA Granisetron Sales, by End User K Tons (2025-2030)
  • Table 494. Middle East Granisetron Sales, by Application K Tons (2025-2030)
  • Table 495. Middle East Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 496. Middle East Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 497. Middle East Granisetron Sales, by End User K Tons (2025-2030)
  • Table 498. Africa Granisetron Sales, by Application K Tons (2025-2030)
  • Table 499. Africa Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 500. Africa Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 501. Africa Granisetron Sales, by End User K Tons (2025-2030)
  • Table 502. North America Granisetron Sales, by Country K Tons (2025-2030)
  • Table 503. North America Granisetron Sales, by Application K Tons (2025-2030)
  • Table 504. North America Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 505. North America Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 506. North America Granisetron Sales, by End User K Tons (2025-2030)
  • Table 507. United States Granisetron Sales, by Application K Tons (2025-2030)
  • Table 508. United States Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 509. United States Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 510. United States Granisetron Sales, by End User K Tons (2025-2030)
  • Table 511. Canada Granisetron Sales, by Application K Tons (2025-2030)
  • Table 512. Canada Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 513. Canada Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 514. Canada Granisetron Sales, by End User K Tons (2025-2030)
  • Table 515. Mexico Granisetron Sales, by Application K Tons (2025-2030)
  • Table 516. Mexico Granisetron Sales, by Forms K Tons (2025-2030)
  • Table 517. Mexico Granisetron Sales, by Drug type K Tons (2025-2030)
  • Table 518. Mexico Granisetron Sales, by End User K Tons (2025-2030)
  • Table 519. Research Programs/Design for This Report
  • Table 520. Key Data Information from Secondary Sources
  • Table 521. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Granisetron: by Application USD Million (2018-2023)
  • Figure 5. Global Granisetron: by Forms USD Million (2018-2023)
  • Figure 6. Global Granisetron: by Drug type USD Million (2018-2023)
  • Figure 7. Global Granisetron: by End User USD Million (2018-2023)
  • Figure 8. South America Granisetron Share (%), by Country
  • Figure 9. Asia Pacific Granisetron Share (%), by Country
  • Figure 10. Europe Granisetron Share (%), by Country
  • Figure 11. MEA Granisetron Share (%), by Country
  • Figure 12. North America Granisetron Share (%), by Country
  • Figure 13. Global Granisetron: by Application K Tons (2018-2023)
  • Figure 14. Global Granisetron: by Forms K Tons (2018-2023)
  • Figure 15. Global Granisetron: by Drug type K Tons (2018-2023)
  • Figure 16. Global Granisetron: by End User K Tons (2018-2023)
  • Figure 17. South America Granisetron Share (%), by Country
  • Figure 18. Asia Pacific Granisetron Share (%), by Country
  • Figure 19. Europe Granisetron Share (%), by Country
  • Figure 20. MEA Granisetron Share (%), by Country
  • Figure 21. North America Granisetron Share (%), by Country
  • Figure 22. Global Granisetron share by Players 2023 (%)
  • Figure 23. Global Granisetron share by Players (Top 3) 2023(%)
  • Figure 24. Global Granisetron share by Players (Top 5) 2023(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Kyowa Kirin (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Kyowa Kirin (Japan) Revenue: by Geography 2023
  • Figure 28. Heron Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Heron Therapeutics (United States) Revenue: by Geography 2023
  • Figure 30. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Fresenius Kabi (Germany) Revenue: by Geography 2023
  • Figure 32. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva (Israel) Revenue: by Geography 2023
  • Figure 36. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Sandoz (Germany) Revenue: by Geography 2023
  • Figure 38. Wockhardt (India) Revenue, Net Income and Gross profit
  • Figure 39. Wockhardt (India) Revenue: by Geography 2023
  • Figure 40. Aristo Pharmaceuticals Pvt Ltd (India) Revenue, Net Income and Gross profit
  • Figure 41. Aristo Pharmaceuticals Pvt Ltd (India) Revenue: by Geography 2023
  • Figure 42. Mankind Pharma Ltd(India) Revenue, Net Income and Gross profit
  • Figure 43. Mankind Pharma Ltd(India) Revenue: by Geography 2023
  • Figure 44. Cipla Ltd (India) Revenue, Net Income and Gross profit
  • Figure 45. Cipla Ltd (India) Revenue: by Geography 2023
  • Figure 46. Global Granisetron: by Application USD Million (2025-2030)
  • Figure 47. Global Granisetron: by Forms USD Million (2025-2030)
  • Figure 48. Global Granisetron: by Drug type USD Million (2025-2030)
  • Figure 49. Global Granisetron: by End User USD Million (2025-2030)
  • Figure 50. South America Granisetron Share (%), by Country
  • Figure 51. Asia Pacific Granisetron Share (%), by Country
  • Figure 52. Europe Granisetron Share (%), by Country
  • Figure 53. MEA Granisetron Share (%), by Country
  • Figure 54. North America Granisetron Share (%), by Country
  • Figure 55. Global Granisetron: by Application K Tons (2025-2030)
  • Figure 56. Global Granisetron: by Forms K Tons (2025-2030)
  • Figure 57. Global Granisetron: by Drug type K Tons (2025-2030)
  • Figure 58. Global Granisetron: by End User K Tons (2025-2030)
  • Figure 59. South America Granisetron Share (%), by Country
  • Figure 60. Asia Pacific Granisetron Share (%), by Country
  • Figure 61. Europe Granisetron Share (%), by Country
  • Figure 62. MEA Granisetron Share (%), by Country
  • Figure 63. North America Granisetron Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Kyowa Kirin (Japan)
  • Heron Therapeutics (United States)
  • Fresenius Kabi (Germany)
  • Hikma Pharmaceuticals (United Kingdom)
  • Teva (Israel)
  • Sandoz (Germany)
  • Wockhardt (India)
  • Aristo Pharmaceuticals Pvt Ltd (India)
  • Mankind Pharma Ltd(India)
  • Cipla Ltd (India)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries Ltd(India) , Biochem Pharmaceutical Industries(India) , Vibcare Pharma Pvt Ltd(India) , Dr Reddy's (India)
Select User Access Type

Key Highlights of Report


Feb 2024 226 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Granisetron Market Quantitative research analysis
Global Granisetron Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Kyowa Kirin (Japan), Heron Therapeutics (United States), Fresenius Kabi (Germany), Hikma Pharmaceuticals (United Kingdom), Teva (Israel), Sandoz (Germany), Wockhardt (India), Aristo Pharmaceuticals Pvt Ltd (India), Mankind Pharma Ltd(India) and Cipla Ltd (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing pharmaceutical research and funding" is seen as one of major influencing trends for Granisetron Market during projected period 2023-2030.
The Granisetron market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Granisetron Market Report?

Have a Query? Click Here

Other Related Reports

Digital Diabetes Management Comprehensive Study by Type (Devices, Digital Diabetes Apps, Data Management Software and Platforms), Device Type (Wearable Devices, Handheld Devices), End User (Self/Home...
$ 3450
Cancer Cachexia Comprehensive Study by Type (Progestogens, Corticosteroids, Combination Therapies, Others), Application (Clinical, Screening, Research), Mechanism of Action (Appetite Stimulators, Wei...
$ 3650
Spironolactones Comprehensive Study by Application (Hospitals, Specialty Clinics, Others), Form (Liquid, Tablet), Dosage Types (Child Dosage (0-17), Adult Dosage (18-64), Senior Dosage (65 and older)...
$ 3350
Rosacea Drugs Comprehensive Study by Type (Antibiotics, Alpha agonists, Retinoids, Corticosteroids, Immunosuppressants, Antihypertensive Agents, Others), Mode of Administration (Topical, Orals), Dist...
$ 3350
Dermal Adhesives Comprehensive Study by Type (Synthetic, Natural), Application (Hospitals, Clinics), End Users (Hospitals, Clinics), Distribution Channel (Online {Company Websites, E-Commerce Website...
$ 3450
Skin Glue Comprehensive Study by Type (Synthetic, Natural), Application (Hospitals, Clinics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Glo...
$ 3500